Jade Biosciences, Inc. Other Nonoperating Expense
Jade Biosciences, Inc. (JBIO) reported Other Nonoperating Expense of $6.00 thousand for the 3-month period ending 2024-06-30, per its 10-Q filed 2024-08-12.
Discontinued › Income Statement › Other Income
us-gaap:OtherNonoperatingExpense · last filed 2024-08-12
- Jade Biosciences, Inc. other nonoperating expense for the quarter ending 2024-06-30 was $6.00K, a 500.00% increase year-over-year.
- Jade Biosciences, Inc. other nonoperating expense for the quarter ending 2024-03-31 was $3.00K, a 200.00% increase year-over-year.
- Jade Biosciences, Inc. other nonoperating expense for the quarter ending 2023-06-30 was $1.00K, a 83.33% decline year-over-year.
- Jade Biosciences, Inc. other nonoperating expense for the quarter ending 2023-03-31 was $1.00K.
- Jade Biosciences, Inc. other nonoperating expense for fiscal 2023 was $1.00K, a 98.73% decline from fiscal 2022.
- Jade Biosciences, Inc. other nonoperating expense for fiscal 2022 was $79.00K, a 2533.33% increase from fiscal 2021.
- Jade Biosciences, Inc. other nonoperating expense for fiscal 2021 was $3.00K, a 0.00% change from fiscal 2020.
- Jade Biosciences, Inc. other nonoperating expense for fiscal 2020 was $3.00K.
| Period end | Other Nonoperating Expense 3 month | Other Nonoperating Expense 6 month | Other Nonoperating Expense 9 month | Other Nonoperating Expense 12 month |
|---|---|---|---|---|
| 2024-06-30 | $6.00K 10-Q · filed 2024-08-12 | $9.00K 10-Q · filed 2024-08-12 | ||
| 2024-03-31 | $3.00K 10-Q · filed 2024-05-13 | |||
| 2023-12-31 | $1.00K 10-K · filed 2024-03-25 | |||
| 2023-06-30 | $1.00K 10-Q · filed 2024-08-12 | $2.00K 10-Q · filed 2024-08-12 | ||
| 2023-03-31 | $1.00K 10-Q · filed 2024-05-13 | |||
| 2022-12-31 | $79.00K 10-K · filed 2024-03-25 | |||
| 2022-06-30 | $6.00K 10-Q · filed 2022-08-15 | $6.00K 10-Q · filed 2022-08-15 | ||
| 2021-12-31 | -$1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | -$1.00K derived: sum of 2 quarters · filed 2023-03-29 | $2.00K derived: sum of 3 quarters · filed 2023-03-29 | $3.00K 10-K · filed 2023-03-29 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $3.00K derived: sum of 2 quarters · filed 2022-08-15 | $4.00K 10-Q · filed 2021-11-15 | |
| 2021-06-30 | $3.00K 10-Q · filed 2022-08-15 | $4.00K 10-Q · filed 2022-08-15 | ||
| 2021-03-31 | $1.00K 10-Q · filed 2022-05-16 | |||
| 2020-12-31 | $3.00K 10-K · filed 2022-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |